Tear Sheet

Company Overview

HTG Molecular Diagnostics, Inc.'s mission is to empower precision medicine at the local level. The company’s proprietary HTG EdgeSeq technology automates multiplexed molecular profiling of nucleic acids in a wide variety of solid and liquid samples, even when very limited in amount. The extraction free workflow paired with detection by next-generation sequencing offers many advantages and enables meaningful applications, such as identifying biomarkers important for precision medicine, understanding the clinical relevance of these biomarkers, and, ultimately, identifying treatment options.

Stock Quote

Copyright Nasdaq. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary HTG Molecular Appoints Michelle R. Griffin to its Board of Directors
TUCSON, Ariz. , Aug. 16, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced the appointment of Ms. Michelle Griffin to its Board of Directors.  “We are pleased to
Toggle Summary HTG Molecular Diagnostics Fulfills First Orders for its Next-Generation Sequencing-Based HTG EdgeSeq Precision Immuno-Oncology Panel
TUCSON, Ariz. , Aug. 15, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced it launched its HTG EdgeSeq Precision Immuno-Oncology Panel and has delivered its first
Toggle Summary HTG Molecular Announces Amendment to Second Statement of Work with QIAGEN Manchester Limited
TUCSON, Ariz. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc.  (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it has entered into an amendment to the second statement of work (“SOW Two”) under
Toggle Summary HTG Molecular Diagnostics Reports Second Quarter 2018 Results
Revenue increased 179% and 190%, respectively, compared to the three and six-month periods in the prior year                Call scheduled for today, August 7 , at 4:30 pm ET TUCSON, Ariz. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc.
Toggle Summary HTG Molecular Diagnostics and Oncologie, Inc. Complete Master Agreement to Partner on Biomarker Development for Immuno-oncology Drug Development
TUCSON, Ariz. , Aug. 03, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications and Oncologie, Inc. an innovative biotechnology company with operations in Boston and Shanghai , today

Stock Chart

SEC Filings

Filing date Description